These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 33275063)
1. 10 years into the resurgence of covalent drugs. De Vita E Future Med Chem; 2021 Jan; 13(2):193-210. PubMed ID: 33275063 [TBL] [Abstract][Full Text] [Related]
2. Covalent Inhibition in Drug Discovery. Ghosh AK; Samanta I; Mondal A; Liu WR ChemMedChem; 2019 May; 14(9):889-906. PubMed ID: 30816012 [TBL] [Abstract][Full Text] [Related]
3. The FDA Oncology Center of Excellence and precision medicine. Goldberg KB; Blumenthal GM; McKee AE; Pazdur R Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511 [TBL] [Abstract][Full Text] [Related]
4. Drug discovery considerations in the development of covalent inhibitors. Mah R; Thomas JR; Shafer CM Bioorg Med Chem Lett; 2014 Jan; 24(1):33-9. PubMed ID: 24314671 [TBL] [Abstract][Full Text] [Related]
5. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins. Yang Y; Shu YZ; Humphreys WG Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335 [TBL] [Abstract][Full Text] [Related]
6. Advances in covalent drug discovery. Boike L; Henning NJ; Nomura DK Nat Rev Drug Discov; 2022 Dec; 21(12):881-898. PubMed ID: 36008483 [TBL] [Abstract][Full Text] [Related]
12. Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy. Das D; Hong J Mini Rev Med Chem; 2020; 20(17):1732-1753. PubMed ID: 32400331 [TBL] [Abstract][Full Text] [Related]
13. Properties of FDA-approved small molecule protein kinase inhibitors. Roskoski R Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063 [TBL] [Abstract][Full Text] [Related]
14. Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors. McAulay K; Hoyt EA; Thomas M; Schimpl M; Bodnarchuk MS; Lewis HJ; Barratt D; Bhavsar D; Robinson DM; Deery MJ; Ogg DJ; Bernardes GJL; Ward RA; Waring MJ; Kettle JG J Am Chem Soc; 2020 Jun; 142(23):10358-10372. PubMed ID: 32412754 [TBL] [Abstract][Full Text] [Related]
15. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. Moore TJ; Furberg CD JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236 [TBL] [Abstract][Full Text] [Related]
16. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit. Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225 [TBL] [Abstract][Full Text] [Related]
17. The Cysteinome of Protein Kinases as a Target in Drug Development. Chaikuad A; Koch P; Laufer SA; Knapp S Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500 [TBL] [Abstract][Full Text] [Related]
18. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Wu P; Nielsen TE; Clausen MH Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956 [TBL] [Abstract][Full Text] [Related]
19. Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials. Naing A Expert Opin Investig Drugs; 2013 Jun; 22(6):679-85. PubMed ID: 23631743 [No Abstract] [Full Text] [Related]
20. Discovery of quinoline-based irreversible BTK inhibitors. de Bruin G; Demont D; de Zwart E; Verkaik S; Hoogenboom N; van de Kar B; van Lith B; Emmelot-van Hoek M; Gulrajani M; Covey T; Kaptein A; Barf T Bioorg Med Chem Lett; 2020 Jul; 30(14):127261. PubMed ID: 32527559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]